Acute Effects of Alemtuzumab Infusion in Patients With Active Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation- United States

doi 10.1212/nxi.0000000000000228

Full Text

Abstract

Available in

Categories

Neurology

Date

Authors

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Endocarditis Following Ocrelizumab in Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2020English

Impact of Alemtuzumab on Health-Related Quality of Life Over 6 Years in CARE-MS II Trial Extension Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis
Neurology
2019English

Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2013English

Natalizumab for Relapsing-Remitting Ms in the Uk Top Cohort

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2014English

Differential Reconstitution of T Cell Subsets Following Immunodepleting Treatment With Alemtuzumab (Anti-Cd52 Monoclonal Antibody) in Patients With Relapsing-Remitting Multiple Sclerosis

Journal of Immunology
AllergyImmunology
2013English

Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
2017English

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
1999English

Antigen Specificity of Clonally Expanded and Receptor Edited Cerebrospinal Fluid B Cells From Patients With Relapsing Remitting MS

Journal of Neuroimmunology
AllergyImmunologyNeurology
2007English

Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy